Expert Opinion on Drug Safety

Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity
pp. 519-523(5)
Author: Guruprasad P Aithal

The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis
pp. 525-534(10)
Authors: Gilbert Bensimon; Adam Doble

Chemotherapy-induced peripheral neurotoxicity
pp. 535-546(12)
Authors: Guido Cavaletti; Paola Marmiroli

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
pp. 547-557(11)
Author: Michael H Davidson

A benefit–risk assessment of class III antiarrhythmic agents
pp. 559-577(19)
Authors: Hanne Elming; Bente Brendorp; Steen Pehrson; Ole Dyg Pedersen; Lars Køber; Christian Torp-Petersen

Mucocutaneous side effects of antineoplastic chemotherapy
pp. 579-587(9)
Authors: B Guillot; D Bessis; O Dereure

Arsenic trioxide in the treatment of haematological malignancies
pp. 589-597(9)
Author: Yok-Lam Kwong

Risks of testosterone replacement therapy in ageing men
pp. 599-606(8)
Authors: R Tan; J Salazar

Disturbance of vision by COX-2 inhibitors
pp. 607-614(8)
Authors: David M Coulter; David WJ Clark

The safety of black cohosh (Actaea racemosa, Cimicifuga racemosa)
pp. 615-623(9)
Author: Alyson Huntley

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis
pp. 625-637(13)
Author: Christopher McCoy

Risk–benefit effects of tocolytic therapy
pp. 639-654(16)
Authors: Peter G Pryde; Susan Janeczek; Robert Mittendorf

Impact of phenytoin therapy on the skin and skin disease
pp. 655-665(11)
Author: Noah Scheinfeld